跳转至内容
Merck

Y0000218

昂丹司琼 盐酸盐 二水合物

European Pharmacopoeia (EP) Reference Standard

别名:

1,2,3,9-四氢-9-甲基-3-[(2-甲基-1H-咪唑-1-基)甲基] -4H-咔唑-4-酮 盐酸盐, GR 38032F

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C18H19N3O · HCl · 2H2O
分子量:
365.85
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

ondansetron

製造商/商標名

EDQM

應用

pharmaceutical (small molecule)

格式

neat

儲存溫度

2-8°C

SMILES 字串

Cl[H].[H]O[H].[H]O[H].Cc1nccn1CC2CCc3c(C2=O)c4ccccc4n3C

InChI

1S/C18H19N3O.ClH.2H2O/c1-12-19-9-10-21(12)11-13-7-8-16-17(18(13)22)14-5-3-4-6-15(14)20(16)2;;;/h3-6,9-10,13H,7-8,11H2,1-2H3;1H;2*1H2

InChI 密鑰

VRSLTNZJOUZKLX-UHFFFAOYSA-N

基因資訊

human ... HTR3A(3359)

正在寻找类似产品? 访问 产品对比指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Ondansetron hydrochloride dihydrate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

生化/生理作用

5-HT3 血清素受体拮抗剂

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

相關產品

产品编号
说明
价格

訊號詞

Danger

危險聲明

危險分類

Acute Tox. 3 Oral - Aquatic Acute 1 - Aquatic Chronic 2 - Eye Dam. 1

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

抱歉,我们目前尚未线上提供该产品的COA。

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

其他客户在看

Slide 1 of 1

1 of 1

João Maria Corrêa Filho et al.
Addictive behaviors, 38(4), 2044-2051 (2013-02-12)
Ondansetron has emerged as a promising medication for the treatment of alcohol dependence, mainly among early-onset alcoholics. This research primarily aimed to evaluate the efficacy and safety of ondansetron at a 16mg/day dosage to treat alcohol-dependent outpatients. A double-blind, placebo-controlled
Daniel Hervás et al.
Pediatric emergency care, 28(11), 1166-1168 (2012-11-02)
In this study, we determine the clinical impact of 1 dose of oral ondansetron for children with vomiting and evaluate the economic consequences of its use. The strategies compared were administering oral ondansetron in addition to oral rehydration therapy (group
Hitendra S Mahajan et al.
Carbohydrate polymers, 91(2), 618-625 (2012-11-06)
The objective of present study was to enhance bioadhesive potential of xyloglucan by thiolation. Thiolation of xyloglucan was achieved with esterification with thioglycolic acid. Thiolated xyloglucan was characterized by NMR, DSC, and XRD analysis. Thiolated xyloglucan was determined to possess
Roger M Browning et al.
Regional anesthesia and pain medicine, 38(1), 39-43 (2012-10-30)
Cesarean delivery is commonly performed under regional anesthesia, which is often associated with maternal shivering. This can cause distress and interfere with monitoring. The study objective was to evaluate the antishivering efficacy of ondansetron, which reduces the incidence and severity
Ali Mujtaba et al.
Drug testing and analysis, 5(2), 122-125 (2013-02-16)
A new, simple, rapid, accurate and precise high performance thin layer chromatography (HPTLC) method has been developed for the estimation of ondansetron hydrochloride in bulk and sublingual tablets. The mobile phase composition was chloroform : ethyl acetate : methanol :

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门